2018 POSTER PRESENTATIONS
Room: Grand Ballroom
Poster Session A
Presenting Monday through Tuesday
Amgen, Inc.
A1. Integrated Cell Culture Continuous Manufacturing (CM) and Real-Time Process Analytical Technology (PAT) Implementation for Biologics Production; Presented by Sherry Y.
BioGenes GmbH
A2. Frequent Challenges of Host Cell Protein ELISA Projects; Presented by Yvonne H.
Bruker Daltonik
A3. Routine Analysis of Host Cell Proteins in Antibody Preparations Using PASEF LC-MS/MS; Presented by Dirk W.
Caprion Biosciences, Inc.
A4. Mass Spectrometry Platforms for High Coverage Process-Specific HCP Identification and Quantitation; Presented by Michael S.
Celgene Corporation
A5. Implementation of an Integrated E2E Bioprocess Development Workflow Platform at Celgene; Presented by James D.
ChromaTan Corporation
A6. Continuous Countercurrent Tangential Chromatography (CCTC) for Capture and Polishing of Monoclonal Antibodies; Presented by Oleg S.
PROAnalytics LLC
A7. RX Series; Presented by Justin L.
ETH Zurich
A8. Twin-Column Counter-Current Chromatography for Purification of Biologics; Presented by Thomas M.
Fluence Analytics
A9. Static Light Scattering Signatures Used to Identify Stability During Formulation Development; Presented by Stephanie M.
Genedata, Inc.
A10. High-Throughput Screening for Best Manufacturing of Cell Lines Using Scale-Down Models; Presented by Andrew L.
Genedata, Inc.
A11. Strategies for Monitoring Host Cell Proteins in Biopharmaceutical Development, Production and Quality Control; Presented by John M.
GenScript USA, Inc.
A12. Biologics IND Application: CMC Platform by GenScript; Presented by Bowu L.
Halo Labs
A13. HORIZON - High Throughput Low Volume Subvisible Particle Analysis; Presented by Bernardo C.
Hebrew Univeristy Jerusalem
A14. Biuret, the AtzE Substrate, Does Not Increase Further Cell Density and Biomass Production in Rhizobium Leguminosarum Bacterial Culture; Presented by Ilana H.
HTL Biosolutions, Inc.
A15. Higher Order Structural Characterization of A Monoclonal Antibody and Its Aggregates During Formulation Development by Using Raman Spectroscopy; Presented by Tiansheng L.
KBIO Osong Medical Innovation Foundation
A16. Strategies for Improving Surfactant Screening by Using Particle Analysis; Presented by Minsik K.
Lonza AG
A17. Platform Approach for Drug Product Simulated Administration Compatibility for Clinical Administration: Concept Study Design and Challenges for Biologics; Presented by Stephanie L.
Lonza Biologics
A18. Use of In Silico and Expression Tools to Support Lead Selection; Presented by Yvette S.
MaxCyte, Inc.
A19. De-Risking Biotherapeutic Development: Maximizing Transient Productivity and Improved Data Relevance Using a Fully Scalable Cell Engineering Technology; Presented by Joan H.
Merck Biodevelopment
A20. Accelerated Formulation Strategy for Monoclonal Antibody; Presented by Alice L.
NanoTemper Technologies
A21. Improving Biologics Workflow-Detailed Characterization of Quality, Binding and Stability of mAbs; Presented by Peter F.
National Research Council Canada
A22. CHO-BRI Inducible Antibody Fed-Batch Production Platform: Impact of Process Parameters on Production Performance; Presented by Phuong Lan P.
PendoTECH
A23. Selection of Suitable Flow Meter Technology for Bioprocess Applications; Presented by Mark M.
Polyplus-Transfection SA
A24. Advanced CHO Cell Expression System for Increased Transient Protein Production; Presented by Geraldine G.
Protein Dynamic Solutions LLC
A25. A High Throughput-Developability and Comparability Assessment (HT-DCA) Platform Providing a Transformative Solution for the Study of Proteins; Presented by Belinda P.
RedShift BioAnalytics, Inc.
A26. Repeatability, Concentration Linearity and High Order Structure Analysis of an IgG1 Sample by Microfluidic Modulation Spectroscopy (MMS); Presented by Jeffrey Z.
Rockland Immunochemicals, Inc.
A27. Evaluation of Novel High Coverage Generic CHO-HCP Reagents; Presented by Anthony F.
Sanofi
A28. Characterization of an Intensified Perfusion Platform at the Cellular Level; Presented by Kristina W.
Teva Pharmaceuticals USA, Inc.
A29. Evaluation of Interactive Effects of Silicone and Tungsten on Protein Quality Attributes; Presented by Naveen R.
Thermo Fisher Scientific
A30. Strategies for High-Titer Protein Expression Using the ExpiCHO and Expi293 Transient Expression Systems; Presented by Chao Yan L.
Thermo Fisher Scientific
A31. ExpiSf: A Chemically Defined Baculovirus-Based Expression System for Enhanced Protein Production in SF9 Cells; Presented by Kenneth T.
U.S. Food and Drug Administration
A32. Utilizing Minimum-Volume Analytical Techniques to Assay the Structural Heterogeneity of IgG1; Presented by Phillip A.
U.S. Food and Drug Administration
A33. Developing Models for Validation of Virus Removal by Continuous Chromatography; Presented by Meng-Jung C.
Unchained Labs
A34. Meet Our Uncle: A Multimodal Instrument for Characterizing Protein Stability; Presented by Lisa A.
University of Connecticut
A35. Detection of Tertiary Structural Changes in Solid State Proteins Using Raman Spectroscopy: Implications for Protein Formulation and Stability; Presented by Lauren F.
Waters Corporation
A36. Identification and Monitoring of Host Cell Proteins in Biopharmaceuticals by a LC/MS Approach in Support of Bioprocess Development; Presented by Weibin C.
Poster Session B
Presenting Wednesday through Thursday
908 Devices, Inc.
B1. An Integrated Benchtop Analyzer for the Rapid Analysis of Cell Growth Media; Presented by Glenn H.
Abbott Laboratories
B2. Single-Step Purification of a His-Tagged Recombinant Fab; Presented by Wan-Ching L.
Amgen, Inc.
B3. Novel High Capacity Protein A Membrane Capture Step for Fc-Based Modalities; Presented by Caleb C.
Bristol-Myers Squibb
B4. Viral Filtration DoE Screening Study for a Biologic Using a Model Bacteriophage; Presented by Zhen T.
Dankook University
B5. Porous 3D Printed Scaffolds with Stem Cell for Guided Bone Regeneration; Presented by Chung Hun O.
Fluid Imaging Technologies, Inc.
B6. FlowCam® Nano Provides Counts, Sizes and Images of Nano-and Microparticles: Application to a Therapeutic Protein Pumping Study; Presented by Dave H.
Genedata, Inc.
B7. An Automated Approach for Comprehensive Characterization and Quantification of Low-Abundance Sequence Variants in a Standard Monoclonal Antibody; Presented by David B.
Genedata, Inc.
B8. End-to-End Workflow Platform for Integrated Biopharmaceutical Development; Presented by Bernie E.
Genedata, Inc.
B9. A Platform Approach to Decrease Developability and Manufacturability Risks of Biologics Molecules; Presented by Amanda F.
Genedata, Inc.
B10. Application of Next Generation Sequencing for Biosafety Assessment of Biologics; Presented by Marcell V.
Genentech, Inc.
B11. Advances in Multi-Product Use Resins; Presented by Yolanda N.
GenScript USA, Inc.
B12. SMAB (Single-Domain Antibody Fused to Monoclonal Antibody) Bispecifics: Achieve Blockbuster Antibody Standards in Next Generation Therapeutics; Presented by Sasidhar M.
Green Cross LabCell
B13. Process Development for Large-Scale Ex-Vivo Expansion of Allogeneic Natural Killer Cells in Stirred-Tank Bioreactor; Presented by Sanghyun L.
HocusLocus, Inc.
B14. Using RNAi and Magnetically Activated Cell Sorting for Cell Line Selection; Presented by Edward E.
ImmunoGen, Inc.
B15. Comprehensive Manipulation of Glycosylation Profiles Across Development Scales; Presented by Kristina L.
Janssen Research and Development
B16. Use of the Cyto-Mine® for Rapid Generation of High-Producing Clonal Cell Lines; Presented by Angela T.
Lawrence Livermore National Laboratory
B17. Development of a Biosorption Process for Recovery of Precious Metals; Presented by Yongqin J.
Lindy Biosciences
B18. Microglassification™: A Novel Dehydration Process Enabling Low Viscosity, Highly Concentrated Injectable Suspensions of Biologics; Presented by Michael D.
MabPlex
B19. Development of Robust Processes for Large Scale Antibody-Drug Conjugation; Presented by Bethanne D.
Magenta Therapeutics
B20. Improvement in Thermal Stability of Antibodies and ADCs with Rationally Chosen Formulations; Presented by Junia D.
MaxCyte, Inc.
B21. Bolstering Therapeutic Efficacy and Speed to Clinic Using Non-Viral T-Cell Engineering; Presented by Krista S.
Merck & Co., Inc.
B22. Epigenome Characterization of CHO Cells; Presented by Amit K.
MockV Solutions LLC
B23. Predicting MVM Clearance by Nanofiltration and Anion Exchange Chromatography Using a Non-Infectious “Mock Virus Particle"; Presented by David C.
Novartis Pharmaceuticals Corporation
B24. Novel Application of AMBR 250 for CAR-T Cell Therapy Bioprocess Automation and Future Commercialization; Presented by Vienna L.
PerkinElmer
B25. Characterization of NIST mAb with Microfluidic CE-SDS Using the Protein Clear HRTM Assay; Presented by James W.
Perkins+Will
B26. Flexible Clean Room Designs; Presented by James L.
Pfizer, Inc.
B27. AMBR250 Modular Demo Summary with Complex Cell Culture Processes; Presented by Inci O.
Polyplus-Transfection SA
B28. Addressing Large-Scale Manufacturing of Clinical Grade Viral Vectors Using an Optimized PEI-Based Transfection Process; Presented by Julien D.
ProZyme, Inc.
B29. High Throughput CE-Based N-Glycan Analysis for Clone Screening in Biotherapeutic Protein Production; Presented by Justin H.
REGENXBIO, Inc.
B30. The Influence of Complexing Time and Transfection Reagents on AAV Production; Presented by Robert S.
REGENXBIO, Inc.
B31. Effect of Transfection Enhancers on AAV Vector Production; Presented by Miguel V.
Roche Pharma Research and Early Development
B32. Downstream Processing of a Monoclonal Bispecific Antibody - A Case Study; Presented by Stefan F.
Rockland Immunochemicals, Inc.
B33. Robust Methods for Anti-Oligonucleotide Antibody Generation; Presented by Daniel K.
Sanofi
B34. Integration of an Automatic Sampling Device with an Intensified Perfusion Platform; Presented by Jared F.
St. Jude Children's Research Hospital
B35. Lentiviral Vector Production from a Stable Packaging Cell Line Using an iCELLis® Bioreactor; Presented by Alicia P.
Thermo Fisher Scientific
B36. Mixing Operations for 50 L to 2000 L Single-Use Mixer: Liquid-Liquid Mixing Characterization and Slurry Suspensions; Presented by Jordan C.
Thermo Fisher Scientific
B37. Monoclonal Antibody Aggregate Removal Using POROS Hydrophobic Interaction Chromatography (HIC) Resins in Bind-Elute Mode; Presented by Stephen H.
U.S. Food and Drug Administration
B38. Integrating High Throughput Analytics with Early-Stage Cell Line Development: A Comprehensive Quality Attribute Characterization of CHO Clone Candidates Expressing a Model IgG1 Antibody; Presented by Casey K.
U.S. Food and Drug Administration
B39. Growth Parameters and Media Dependent Effects on Antibody Product Quality: Glycosylation and Aglycosylation; Presented by David P.
UBE Industries, Ltd.
B40. Novel Bioreactor System for Continuous IgG Production; Presented by Masahiko H.
University of Connecticut
B41. Freeze-Drying of Highly Concentrated Proteins: Effect of Formulation and Processing on Phase Composition, Porous Structure and Reconstitution Time; Presented by Shreya K.
University of Manchester
B42. Liquid-Liquid Equilibrium of a Monoclonal Antibody in Terms of Protein-Protein Interactions; Presented by Nicole S.
University of Natural Resources and Life Sciences (BOKU)
B43. Critical Quality Attributes in Recombinant IgM Production and How They Are Influenced by External Process Conditions; Presented by Julia H.
University of Natural Resources and Life Sciences (BOKU)
B44. Automated, High-Throughput Content Analysis in Process Development; Presented by Martin V.
Waters Corporation
B45. Improving Glycan Profiling in Process Development Using Spectral Library; Presented by Ximo Z.
SCIEX Separations
B46. Repeatability of the C100HT Biologics Analyzer, a High Throughput Glycan Screening Platform; Presented by Mark L.